Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2019
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
A Amatu, A Sartore-Bianchi, K Bencardino, et al.
ESMO Open
|
May 27, 2021
Strategies to tackle RAS-mutated metastatic colorectal cancer
G Patelli, F Tosi, A Amatu, et al.
Cancer Treatment Reviews
|
December 7, 2010
Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer
A Sartore-Bianchi, K Bencardino, A Cassingena, et al.
Cardiovascular and Interventional Radiology
|
September 4, 2009
OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma
Guido Poggi, A Amatu, B Montagna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 4, 2017
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor
G Siravegna, A Sartore-Bianchi, B Mussolin, et al.
ESMO Open
|
December 17, 2021
Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management
P Vallerio, A Orenti, F Tosi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2015
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
C Cremolini, M Di Bartolomeo, A Amatu, et al.
ESMO Open
|
August 20, 2021
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study
A Raimondi, G Fucà, A G Leone, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Patient-Reported Experience Measures (PREMs) in patients with metastatic colorectal cancer undergoing treatment supported by feedback auditing: the EPIC study
A Sartore-Bianchi, F Toscano, D P Bernasconi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 27, 2016
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer
A Amatu, L Barault, C Moutinho, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2019
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
A Amatu, A Sartore-Bianchi, K Bencardino, et al.
ESMO Open
|
May 27, 2021
Strategies to tackle RAS-mutated metastatic colorectal cancer
G Patelli, F Tosi, A Amatu, et al.
Cancer Treatment Reviews
|
December 7, 2010
Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer
A Sartore-Bianchi, K Bencardino, A Cassingena, et al.
Cardiovascular and Interventional Radiology
|
September 4, 2009
OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma
Guido Poggi, A Amatu, B Montagna, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 4, 2017
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor
G Siravegna, A Sartore-Bianchi, B Mussolin, et al.
ESMO Open
|
December 17, 2021
Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management
P Vallerio, A Orenti, F Tosi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2015
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
C Cremolini, M Di Bartolomeo, A Amatu, et al.
ESMO Open
|
August 20, 2021
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study
A Raimondi, G Fucà, A G Leone, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Patient-Reported Experience Measures (PREMs) in patients with metastatic colorectal cancer undergoing treatment supported by feedback auditing: the EPIC study
A Sartore-Bianchi, F Toscano, D P Bernasconi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 27, 2016
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer
A Amatu, L Barault, C Moutinho, et al.
Page
of 2